Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2026)

Castle Biosciences has disclosed Accumulated Expenses across 9 years of filings, most recently posting $19.1 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $19.1 million, up 7.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.1 million (up 7.02% YoY), and the FY2025 annual result was $38.3 million, up 17.61% from the prior year.
• Accumulated Expenses came in at $19.1 million for Q1 2026 at Castle Biosciences, down from $38.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $38.3 million in Q4 2025 to a low of $8.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $21.2 million (2024), against an average of $22.2 million.
• Across the five-year window, Accumulated Expenses soared 73.0% in 2022 and advanced 7.02% in 2026, its largest moves.
• Castle Biosciences' Accumulated Expenses stood at $24.4 million in 2022, then gained by 18.83% to $28.9 million in 2023, then gained by 12.47% to $32.6 million in 2024, then gained by 17.61% to $38.3 million in 2025, then plunged by 50.08% to $19.1 million in 2026.
• The last three Accumulated Expenses figures came in at $19.1 million (Q1 2026), $38.3 million (Q4 2025), and $31.8 million (Q3 2025), per Business Quant data.